GO:0039654 fusion of virus membrane with host endosome membrane: Viral Entry Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0039654 describes the fusion of a virus membrane with a host endosome membrane, a process that occurs after endocytic internalization and releases the viral genome or contents into the cytoplasm.
• This process is a hallmark of enveloped virus entry, including influenza virus, filoviruses, and SARS-CoV-2, and is often triggered by the low pH of the endosome [1,4,5].
• Key viral proteins such as influenza hemagglutinin (HA), Ebola glycoprotein (GP), and SARS-CoV-2 spike (S) mediate membrane fusion, while host factors like IFITM3 and LY6E regulate the process [2,4,6].
• Host endosomal lipids, including sphingolipids and cholesterol, are critical for efficient fusion and are emerging as antiviral targets.
• Defects or alterations in endosomal fusion influence viral pathogenesis and are linked to severe diseases such as COVID-19 and viral hemorrhagic fevers [4,8].
• CRISPR-based knockout, knock-in, and overexpression models enable functional dissection of viral and host genes involved in endosomal membrane fusion [2,6].
Description
Fusion of virus membrane with host endosome membrane (GO:0039654) is a biological process that defines a critical step in the entry of many enveloped viruses. After a virus is internalized via endocytosis, it is delivered to the endosome, where the viral membrane fuses with the endosomal membrane, releasing the viral genome or nucleocapsid into the cytoplasm. This process is essential for the replication cycle of viruses such as influenza A virus, Ebola virus, and SARS-CoV-2, and it represents a key target for antiviral intervention [1,4,5]. Understanding the molecular details of this fusion event is fundamental for researchers studying viral pathogenesis, host-pathogen interactions, and the development of entry inhibitors. The low pH environment of the endosome often serves as a trigger for conformational changes in viral fusion proteins, enabling them to mediate membrane merger [1,3]. Host factors, including interferon-induced transmembrane proteins (IFITMs) and lipid-modifying enzymes, can restrict or promote this step, highlighting the complex interplay between virus and host [2,6,7]. This article provides a comprehensive overview of the ontology, mechanisms, key genes, disease relevance, and experimental models for studying GO:0039654.
fusion of virus membrane with host endosome membrane At A Glance
| GO ID | GO:0039654 |
|---|---|
| GO term | fusion of virus membrane with host endosome membrane |
| Ontology | biological_process |
| Synonym | viral entry into host cell via endocytosis followed by membrane fusion with the endosome membrane |
| Major function | Release of viral contents into the host cell cytoplasm after endosomal internalization |
| Related process | Viral entry into host cell, endocytosis, membrane fusion |
| Cellular location | Host endosome membrane, viral envelope |
| Trigger | Often low pH in endosomes, proteolytic cleavage of viral fusion proteins |
| Organisms | Enveloped viruses including influenza virus, filoviruses, coronaviruses |
What Is GO:0039654?
GO:0039654 is defined as the fusion of a virus membrane with a host endosome membrane. This process occurs after the virus is internalized through the endosomal pathway and results in the release of the virus contents into the cell. It is a biological process that specifically describes the membrane merger event between the viral envelope and the endosomal membrane, distinguishing it from other entry routes such as plasma membrane fusion or macropinocytosis.
Why Is fusion of virus membrane with host endosome membrane Important in Cell Biology?
GO:0039654 is important because it represents a decisive step in the life cycle of many medically significant enveloped viruses. Fusion with the endosome membrane allows the viral genome to access the cytoplasm, initiating infection. This process is a prime target for antiviral drugs and vaccines, as blocking fusion can prevent infection. Moreover, host factors that regulate endosomal fusion, such as IFITM3 and LY6E, are critical determinants of viral tropism and pathogenesis [2,6]. Studying this process also sheds light on fundamental cell biology of membrane trafficking and fusion.
• It is a required step for the entry of influenza A virus, where hemagglutinin (HA) mediates fusion in late endosomes.
• Filoviruses such as Ebola virus use this route to enter host cells, with glycoprotein (GP) driving fusion.
• SARS-CoV-2 can enter via endosomal fusion, and its fusion peptide interacts with endosomal membranes.
• Host restriction factor IFITM3 blocks influenza virus entry by altering lipid order and stabilizing hemifusion, directly impacting GO:0039654.
• LY6E is a conserved host defense factor that regulates coronavirus entry, including endosomal fusion steps.
• Sphingolipid metabolism in the endosome influences membrane fusion efficiency and viral infection.
• Defects in endosomal trafficking and fusion are linked to severe COVID-19 and viral hemorrhagic fevers [4,8].
• Understanding this process aids in the design of broad-spectrum antivirals targeting fusion.
• It provides a model for studying general membrane fusion mechanisms in cell biology.
• CRISPR screens can identify host genes essential for endosomal fusion, revealing new therapeutic targets [2,6].
What Happens During fusion of virus membrane with host endosome membrane?
Endocytic Uptake and Delivery to Endosomes
In simple terms: The virus is taken into the cell in a bubble and delivered to a sorting compartment called the endosome.
Many enveloped viruses enter host cells via endocytosis, including clathrin-mediated and caveolin-mediated pathways. After internalization, the virus-containing vesicle traffics to early endosomes and then to late endosomes or lysosomes. The endosomal environment becomes progressively more acidic, which is a key trigger for fusion. For influenza virus, the low pH of the late endosome activates the hemagglutinin (HA) protein to mediate fusion. Similarly, filoviruses are internalized and trafficked to endosomes where proteolytic processing of the glycoprotein (GP) by cathepsins occurs, enabling fusion.
Conformational Changes in Viral Fusion Proteins
In simple terms: The viral fusion protein changes shape when it senses the endosome environment, exposing a part that can insert into the host membrane.
Viral fusion proteins are typically metastable and undergo dramatic conformational rearrangements upon triggering. For influenza HA, low pH induces a transition from the prefusion to the postfusion state, exposing the fusion peptide that inserts into the endosomal membrane [1,3]. For SARS-CoV-2, the spike protein is cleaved by proteases such as TMPRSS2 or cathepsins, and the fusion peptide is exposed to interact with the endosomal membrane. This step is critical for overcoming the energy barrier to membrane fusion.
Membrane Merger and Hemifusion
In simple terms: The viral and endosome membranes merge halfway, forming a bridge, and then open a pore to release the viral contents.
The fusion process proceeds through a hemifusion intermediate, where the outer leaflets of the viral and endosomal membranes merge while the inner leaflets remain separate. This step is regulated by host lipids and proteins. IFITM3 has been shown to block influenza virus entry by sorting lipids and stabilizing hemifusion, preventing the formation of a full fusion pore. Sphingolipids and cholesterol in the endosomal membrane also modulate fusion efficiency. Ultimately, a fusion pore forms, allowing the viral ribonucleoprotein complexes or genome to enter the cytoplasm.
Release of Viral Contents and Initiation of Infection
In simple terms: Once the pore opens, the virus's genetic material spills into the cell, starting the infection.
After fusion pore formation, the viral genome or nucleocapsid is released into the cytoplasm. For influenza virus, the viral ribonucleoproteins are imported into the nucleus for replication. For coronaviruses, the positive-sense RNA genome is translated directly. This release marks the successful completion of GO:0039654 and the beginning of viral replication. Host factors such as LY6E can interfere with this step, as LY6E restricts coronavirus entry by modulating the endosomal fusion process.
Host Factors and Regulation of Fusion
In simple terms: The cell has its own proteins that can help or block the virus from fusing with the endosome.
Host cells express multiple factors that regulate endosomal membrane fusion. Interferon-induced transmembrane proteins (IFITMs) are broad-spectrum antiviral factors that block fusion of many enveloped viruses. IFITM3 restricts influenza virus by altering membrane lipid order and stabilizing hemifusion. LY6E, a glycosylphosphatidylinositol-anchored protein, is a conserved host defense factor against coronaviruses; its expression is regulated by GPI biosynthesis, and it interferes with endosomal fusion. Additionally, sphingolipid metabolism enzymes modulate the lipid composition of endosomes, affecting fusion efficiency. These host-virus interactions are active areas of research.
Key Genes Involved in GO:0039654 fusion of virus membrane with host endosome membrane
The following genes and proteins are central to the process of fusion of virus membrane with host endosome membrane, either as viral fusogens or host regulatory factors.
| Gene | Major Role | Research Relevance |
|---|---|---|
| HA (influenza) | Viral hemagglutinin mediates fusion at low pH | Model for pH-triggered fusion; target of antivirals |
| GP (Ebola) | Filovirus glycoprotein mediates fusion after proteolytic processing | Key for filovirus entry; studied in BSL-4 |
| S (SARS-CoV-2) | Spike protein mediates fusion with endosomal or plasma membrane | Critical for COVID-19 entry; target of vaccines |
| IFITM3 | Host restriction factor that blocks fusion by stabilizing hemifusion | Broad antiviral; regulates lipid order |
| LY6E | Host defense factor that restricts coronavirus fusion | Regulated by GPI biosynthesis; interferon-induced |
| CTSB | Cathepsin B, proteolytically activates Ebola GP | Required for filovirus entry |
| CTSL | Cathepsin L, activates SARS-CoV-2 spike for fusion | Potential drug target |
| TMPRSS2 | Protease that cleaves spike at plasma membrane | Alternative entry route; not endosomal |
| NPC1 | Endosomal cholesterol transporter, Ebola receptor | Essential for filovirus fusion |
| SMPD1 | Acid sphingomyelinase, generates ceramide for fusion | Lipid metabolism affects fusion |
| GBA | Glucocerebrosidase, affects sphingolipid balance | Modulates endosomal membrane composition |
| PIKFYVE | Lipid kinase, regulates endosomal phosphatidylinositol | Influences endosomal trafficking and fusion |
| RAB7 | Late endosome marker, regulates fusion | Controls endosomal maturation |
| LAMP1 | Lysosomal-associated membrane protein | Endosomal marker; may affect fusion |
| VPS34 | Phosphatidylinositol 3-kinase, endosomal sorting | Regulates endosome function |
| ATG5 | Autophagy-related, affects endosomal membrane | Cross-talk with fusion |
| GPI biosynthesis genes | Regulate LY6E expression and coronavirus defense | Host defense pathway |
How Is fusion of virus membrane with host endosome membrane Regulated?
The process of fusion of virus membrane with host endosome membrane is regulated at multiple levels. Viral fusion proteins are activated by proteolytic cleavage and low pH, which are tightly controlled by endosomal maturation. Host cells regulate endosomal pH and lipid composition through ion channels and lipid-modifying enzymes. Interferon signaling induces restriction factors such as IFITM3 and LY6E, which directly inhibit fusion [2,6]. Sphingolipid metabolism also modulates membrane fluidity and fusion efficiency. Additionally, endosomal trafficking pathways controlled by Rab GTPases and phosphoinositides determine whether the virus reaches the fusion-competent compartment.
fusion of virus membrane with host endosome membrane and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| IFITM3 | Severe influenza, viral restriction | KO and overexpression in A549 cells |
| NPC1 | Niemann-Pick disease C, Ebola entry | KO in HeLa cells, patient fibroblasts |
| LY6E | Coronavirus restriction, GPI biosynthesis | KO and knock-in in HEK293T |
| SMPD1 | Niemann-Pick disease A/B, sphingolipid metabolism | KO in Huh7 cells |
| CTSL | SARS-CoV-2 entry, protease activation | KO in Calu-3 cells |
Influenza and Viral Pneumonia
Influenza A virus relies on endosomal fusion to initiate infection. The viral hemagglutinin (HA) is activated by low pH in late endosomes, and fusion releases the viral genome. Host factor IFITM3 restricts this step, and polymorphisms in IFITM3 are associated with severe influenza in humans [1,2]. Understanding this process is critical for developing antivirals that block fusion.
Ebola Virus Disease
Ebola virus enters host cells via endocytosis and fuses with the endosomal membrane after proteolytic processing of its glycoprotein (GP) by cathepsins. The endosomal cholesterol transporter NPC1 is essential for this fusion step. Defects in NPC1 cause Niemann-Pick disease, and Ebola virus uses NPC1 as a receptor. This highlights the link between endosomal biology and viral hemorrhagic fevers.
COVID-19
SARS-CoV-2 can enter cells through endosomal fusion, particularly in cells with low TMPRSS2 expression. The spike protein's fusion peptide interacts with endosomal membranes, and this step is a target for antiviral drugs. Host factors such as LY6E restrict coronavirus entry by interfering with endosomal fusion, and GPI biosynthesis regulates LY6E levels [5,6]. Dysregulation of endosomal trafficking is also observed in severe COVID-19.
Sphingolipid Disorders and Viral Susceptibility
Sphingolipid metabolism influences endosomal membrane fusion. Mutations in enzymes such as SMPD1 (acid sphingomyelinase) or GBA (glucocerebrosidase) alter lipid composition and can affect viral entry. These genes are linked to lysosomal storage disorders, and patients may have altered susceptibility to enveloped viruses.
From fusion of virus membrane with host endosome membrane-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does gene X restrict influenza fusion? | IFITM3 KO A549 cells + influenza infection |
| Does gene Y affect Ebola entry? | NPC1 KO HeLa cells + Ebola GP pseudovirus |
| Is LY6E required for coronavirus restriction? | LY6E KO HEK293T + SARS-CoV-2 spike pseudovirus |
| Does sphingolipid enzyme Z modulate fusion? | SMPD1 KO Huh7 + influenza or coronavirus |
| Can a point mutation in HA alter pH threshold? | HA point-mutant influenza virus |
| Does overexpression of a host factor block fusion? | Stable overexpression of IFITM3 in A549 |
How to Study the fusion of virus membrane with host endosome membrane Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Pseudovirus entry assay | Viral entry efficiency | Testing host gene KO or overexpression |
| CRISPR knockout screen | Genes required for entry | Genome-wide discovery |
| Live-cell imaging | Endosomal trafficking and fusion | Visualizing fusion events |
| Liposome fusion assay | Membrane merger kinetics | Studying lipid requirements |
| qRT-PCR | Viral RNA release | Quantifying fusion efficiency |
| Western blot | Viral protein cleavage | Assessing protease activation |
| RNA-seq | Host gene expression changes | Identifying interferon-stimulated genes |
| Proteomics | Protein interactions in endosomes | Mapping host-virus complexes |
Pseudovirus Entry Assays
Pseudoviruses bearing viral fusion proteins (e.g., SARS-CoV-2 spike, Ebola GP) and a reporter gene are used to measure entry. These assays can be performed in KO or overexpression cell lines to dissect the role of host genes in endosomal fusion. They are safe and quantitative [4,6].
Fluorescence Microscopy and Live Imaging
Imaging of viral particles labeled with lipophilic dyes or fluorescent proteins allows visualization of endosomal trafficking and fusion. pH-sensitive dyes can report fusion pore formation. This method provides spatial and temporal resolution of GO:0039654.
CRISPR Screens
Genome-wide CRISPR knockout screens have identified host genes required for viral entry, including endosomal fusion. For example, screens with Ebola or SARS-CoV-2 have revealed NPC1, CTSL, and others. These screens are powerful for discovering new regulators [4,6].
Biochemical Fusion Assays
In vitro fusion assays using liposomes and purified viral fusion proteins can reconstitute membrane merger. These assays measure lipid mixing and content release, and are used to study the mechanism of fusion and the effect of lipids like sphingolipids.
How CRISPR Can Be Used to Study GO:0039654 fusion of virus membrane with host endosome membrane
Knockout
CRISPR knockout of host genes such as IFITM3, NPC1, or LY6E allows researchers to test their requirement for endosomal fusion. For example, IFITM3 KO cells show enhanced influenza entry, confirming its restrictive role. NPC1 KO cells are resistant to Ebola virus entry. These models are essential for validating host factors identified in screens.
Point Mutation
Point mutations can be introduced into viral fusion proteins (e.g., HA, spike) or host genes to study specific residues. For instance, mutating the pH-sensing residues in influenza HA alters the threshold for fusion. Host gene point mutations can mimic natural polymorphisms, such as IFITM3 rs12252, to study their impact on viral restriction.
Knock-in
Knock-in of tagged versions of host proteins (e.g., GFP-LY6E) allows visualization and immunoprecipitation. Knock-in of viral receptors or fusion proteins into model cell lines can create permissive cells for studying entry. This approach helps track protein localization during endosomal fusion.
Overexpression
Overexpression of host restriction factors like IFITM3 or LY6E can block viral fusion and is used to study their antiviral mechanisms. Overexpression of viral fusion proteins can also be used to study their fusogenic activity in cell-cell fusion assays [2,6].
How EDITGENE Supports fusion of virus membrane with host endosome membrane Research
Researchers studying fusion of virus membrane with host endosome membrane-related genes often need to determine whether a candidate gene is causally involved in viral entry or host restriction. EDITGENE provides comprehensive CRISPR services to generate knockout, point-mutation, knock-in, and overexpression cell models, as well as library screening and bioinformatics support, enabling rigorous functional studies of GO:0039654.
Contact EDITGENE today to design your custom CRISPR model for fusion of virus membrane with host endosome membrane research.
Frequently Asked Questions About fusion of virus membrane with host endosome membrane
What is GO:0039654?
GO:0039654 is the Gene Ontology term for fusion of virus membrane with host endosome membrane, a biological process where enveloped viruses fuse with the endosome after endocytosis to release their contents into the cell.
What genes are involved in fusion of virus membrane with host endosome membrane?
Key genes include viral fusion proteins like influenza HA, Ebola GP, and SARS-CoV-2 spike, as well as host factors such as IFITM3, LY6E, NPC1, CTSB, CTSL, and sphingolipid metabolism enzymes [1,2,4,5,6,7].
How does influenza virus fuse with the endosome membrane?
Influenza virus is internalized into endosomes, where low pH triggers a conformational change in hemagglutinin (HA), exposing the fusion peptide that inserts into the endosomal membrane and mediates fusion.
What is the role of IFITM3 in endosomal fusion?
IFITM3 is a host restriction factor that blocks influenza virus fusion by sorting lipids and stabilizing hemifusion, preventing the formation of a full fusion pore.
Can SARS-CoV-2 enter cells via endosomal fusion?
Yes, SARS-CoV-2 can enter via endosomal fusion, especially in cells with low TMPRSS2. The spike protein's fusion peptide interacts with endosomal membranes, and this step is a target for antivirals.
What host factors regulate endosomal membrane fusion?
Host factors include IFITM3, LY6E, NPC1, cathepsins, sphingolipid enzymes, and endosomal trafficking proteins like Rab7 and PIKFYVE [2,4,6,7,8].
How can CRISPR be used to study GO:0039654?
CRISPR knockout, knock-in, and overexpression models allow functional testing of host and viral genes in endosomal fusion, using pseudovirus entry assays and imaging [2,4,6].
What diseases are associated with defects in endosomal fusion?
Diseases include severe influenza, Ebola virus disease, COVID-19, and lysosomal storage disorders like Niemann-Pick disease that affect endosomal lipid composition [1,2,4,5,7].
What methods are used to measure endosomal fusion?
Methods include pseudovirus entry assays, live-cell imaging, liposome fusion assays, CRISPR screens, and biochemical assays for lipid mixing [3,4,6,7].
Why is endosomal fusion important for antiviral drug development?
Because it is a required step for many enveloped viruses, blocking endosomal fusion can prevent infection. It is a target for entry inhibitors and vaccines [1,3,5].
Conclusion
GO:0039654, fusion of virus membrane with host endosome membrane, is a fundamental biological process that enables enveloped viruses to deliver their genomes into host cells. It involves a complex interplay between viral fusion proteins, host endosomal lipids, and restriction factors. Understanding this process is essential for developing antiviral strategies against influenza, Ebola, COVID-19, and other viral diseases. CRISPR-based models and advanced screening methods continue to uncover new host factors and mechanisms, offering promising avenues for therapeutic intervention.
References
- 1. Luo M. 2012. Influenza virus entry.. Adv Exp Med Biol 726:201-21 PMID: 22297515
- 2. Klein S et al.. 2023. IFITM3 blocks influenza virus entry by sorting lipids and stabilizing hemifusion.. Cell Host Microbe 31(4):616-633.e20 PMID: 37003257
- 3. Harrison SC. 2015. Viral membrane fusion.. Virology 479-480:498-507 PMID: 25866377
- 4. Simmons G. 2013. Filovirus entry.. Adv Exp Med Biol 790:83-94 PMID: 23884587
- 5. Schaefer SL et al.. 2021. Binding of SARS-CoV-2 Fusion Peptide to Host Endosome and Plasma Membrane.. J Phys Chem B 125(28):7732-7741 PMID: 34255499
- 6. Ma Y et al.. 2025. Glycosylphosphatidylinositol biosynthesis functions as a conserved host defense pathway against coronaviruses via regulation of LY6E.. PLoS Pathog 21(9):e1013441 PMID: 40901862
- 7. Dai J et al.. 2024. Virus infection and sphingolipid metabolism.. Antiviral Res 228:105942 PMID: 38908521
- 8. Mironov AA et al.. 2023. COVID-19 Biogenesis and Intracellular Transport.. Int J Mol Sci 24(5) PMID: 36901955
